CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 32 enrolled
Drug / intervention
Letermovirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04904614
NCT04904614Phase 4Completed
CompareCT.gov

Evaluation of the Tolerability and Clinical Effectiveness of Letermovir in Heart Transplantation

Tufts Medical Center·interventional·Posted May 27, 2021·Updated Jul 29, 2025

In Brief

A Phase 4 clinical trial evaluating Letermovir for Cytomegalovirus Disease and 4 related conditions. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This is an open label trial in which letermovir will be given as prophylaxis for the prevention of cytomegalovirus (CMV) infection and disease to all heart transplants who are at risk for cytomegalovirus. The study will compare a 30 patient prospective cohort to a retrospective cohort of 374 heart transplant recipients for the rates of neutropenia. In addition, the tolerability of letermovir will be assessed in this population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedMay 27, 2021
Enrollment StartJan 5, 2022
Primary CompletionJan 14, 2025
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.1 years ago

Interventions

Letermovirdrug

Open label trial of the licensed drug, letermovir, in a population of heart transplant recipients for which it is not yet licensed